Equillium (EQ) Gains from Investment Securities (2017 - 2025)
Equillium (EQ) reported Gains from Investment Securities of $11.3 million for Q3 2025, up 19396.67% year-over-year from N/an in Q3 2024, and up 13.82% quarter-over-quarter from $9.9 million in Q2 2025.
Equillium (EQ) Gains from Investment Securities (2017 - 2025) Analysis & Trends
Equillium (EQ) has 9 years of Gains from Investment Securities data on file, last reported at $11.3 million in Q3 2025.
- Gains from Investment Securities for Q3 2025 came in at $11.3 million, up 19396.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.7 million (down 37.24% YoY), and the FY2025 annual result was $10.4 million, up 15.41% from the prior year.
- Gains from Investment Securities advanced to $11.3 million in Q3 2025 per EQ's latest filing, from $9.9 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $11.3 million in Q3 2025 and troughed at $43135.0 in Q4 2021.
- A 5-year average of $4.1 million and a median of $2.2 million in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities plunged 99.19% in 2024, then soared 19396.67% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $43135.0 in 2021, then jumped by 11729.14% to $5.1 million in 2022, then surged by 37.8% to $7.0 million in 2023, then climbed by 28.34% to $9.0 million in 2024, then grew by 24.99% to $11.3 million in 2025.
- Business Quant data shows EQ's Gains from Investment Securities at $11.3 million in Q3 2025, $9.9 million in Q2 2025, and $645182.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 11.28 Mn |
| Sep 30, 2025 | 11.28 Mn |
| Jun 30, 2025 | 9.91 Mn |
| Jun 30, 2025 | 9.91 Mn |
| Mar 31, 2025 | 645,182.00 |
| Mar 31, 2025 | 645,182.00 |
| Dec 31, 2024 | 9.02 Mn |
| Dec 31, 2024 | 9.02 Mn |
| Sep 30, 2024 | 57,848.00 |
| Sep 30, 2024 | 57,848.00 |
| Jun 30, 2024 | 2.21 Mn |
| Jun 30, 2024 | 2.21 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Dec 31, 2023 | 7.03 Mn |
| Dec 31, 2023 | 7.03 Mn |
| Sep 30, 2023 | 7.17 Mn |
| Sep 30, 2023 | 7.17 Mn |
| Jun 30, 2023 | 106,602.00 |
| Jun 30, 2023 | 106,602.00 |